about
Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesOptimal Use of Vaccines for Control of Influenza A Virus in SwineA miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigensCross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.Heterologous challenge in the presence of maternally-derived antibodies results in vaccine-associated enhanced respiratory disease in weaned piglets.Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.Methods for analysis of cell-mediated immunity in domestic animal species.Role of terrestrial wild birds in ecology of influenza A virus (H5N1)Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Live attenuated influenza vaccine provides superior protection from heterologous infection in pigs with maternal antibodies without inducing vaccine-associated enhanced respiratory disease.Analysis of cytokine secretion from human plasmacytoid dendritic cells infected with H5N1 or low-pathogenicity influenza viruses.A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses.NFkappaB negatively regulates interferon-induced gene expression and anti-influenza activity.Factors affecting induction of peripheral IFN-γ recall response to influenza A virus vaccination in pigs.Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines.An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.Divergent immune responses and disease outcomes in piglets immunized with inactivated and attenuated H3N2 swine influenza vaccines in the presence of maternally-derived antibodies.Analyzing swine sera for functional antibody titers against influenza A neuraminidase proteins using an enzyme-linked lectin assay (ELLA).Induction of T lymphocytes specific for bovine viral diarrhea virus in calves with maternal antibody.Vaccination with NS1-truncated H3N2 swine influenza virus primes T cells and confers cross-protection against an H1N1 heterosubtypic challenge in pigs.Influenza virus NS1 protein protects against lymphohematopoietic pathogenesis in an in vivo mouse model.T cells from a high proportion of apparently naive cattle can be activated by modified vaccinia virus Ankara (MVA).Priming of multiple T cell subsets by modified-live and inactivated bovine respiratory syncytial virus vaccines.T-cell populations responsive to bovine respiratory syncytial virus in seronegative calves.Evaluation of the HIV Infant Tracking System (HITSystem) to optimise quality and efficiency of early infant diagnosis: a cluster-randomised trial in KenyaThe type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory diseaseInfant HIV testing at birth using point-of-care and conventional HIV DNA PCR: an implementation feasibility pilot study in Kenya
P50
Q24615003-F5952878-ECBA-47EC-AC0D-CBF0B20ADABFQ26783503-093C4EE3-A25C-4E0F-A613-494AB62447EEQ28830491-14CE3F0A-D736-4FB8-A2B2-A8AECA81D990Q30359842-9C75F61E-0C82-42F0-B564-279942BA0674Q30384443-BD830216-4462-48C2-A129-6EC4DF38673DQ30395315-D01B369D-19B6-416B-9E9B-4F7D04C389AFQ35877371-A3A9ACD0-2580-4D83-864E-CCEA6CE0E733Q36034001-637F2BB8-B16F-4F42-8189-6DCE7D642344Q36075789-06F60A69-A34B-403B-9215-F299BEEDEF92Q36276647-831F5025-6C0E-43A2-8D1A-0990EC1452E9Q37036836-AF40D385-4704-4199-BADB-1D1FD08B9D66Q37626927-B4153253-59AC-4AE6-ADD7-9A83864DA606Q38315256-83AA638C-4F55-4F90-91D0-9796A8D6F0F3Q38939171-248064E4-A0A2-4ADA-AC4E-2C1024384B37Q39668475-8123D24B-AB7A-44FE-A560-A14DED716AE5Q40734248-2E9A4EC4-45C5-421B-90DB-AD3F68AB8528Q42186897-A5753AB7-88BC-4D84-B2C1-6711A60D2757Q42204943-1A4DFB0F-4EB9-4B2A-B815-3142B557D1A6Q42214414-80A2B6BE-3167-403E-91F7-E28AF47FD2FAQ42983862-8F3D4B4B-1659-42DA-93B7-A230C40B4F37Q45361895-90323B7A-F65A-4EDC-9FC6-F52E52EC6034Q45418731-EF274D64-617E-4569-8B4D-F80D15C0C553Q45666562-C2DD9F9D-7C7E-44E4-A61B-49F2E8B225CFQ45721898-26AF507A-F34D-4DE7-901F-8902432A883FQ45733873-BE6282F0-E6F9-491B-B4A5-0B41EE71C345Q57481820-CA0353F3-80C5-41B2-959D-43DB892267E3Q59353304-B496E1B0-6152-4DAC-B98F-00EC203E33FBQ61443802-81B17940-F8AF-4300-9FFC-836D22A95713
P50
name
Matthew R Sandbulte
@en
type
label
Matthew R Sandbulte
@en
prefLabel
Matthew R Sandbulte
@en